Emergent BioSolutions Inc. EBS
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- -44.90%
- 1 year
- -46.96%
- Open
- 7.11
- Prev close
- 7.22
- Mkt cap
- 349.17M
- Vol
- 754.44K
- Avg vol
- 1.23M
- EPS
- -3.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.77
- High
- 7.30
- Forward P/E
- 2.73
- Beta
- 1.57
- Short ratio
- 4.54
- Inst. own
- 60.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 9.27
- 200-d avg
- 7.13
- 1y target
- 12.00
5D chart
Signals (76)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 10:15 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| RSI: Overbought | Oct 29, 3:55 PM | 2 days ago |
| RSI: Overbought | Oct 29, 3:45 PM | 2 days ago |
| RSI: Overbought | Oct 29, 3:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 3 days ago |
| RSI: Overbought | Oct 28, 11:25 AM | 3 days ago |
| RSI: Overbought | Oct 28, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:00 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 5 days ago |
| RSI: Overbought | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
News
3 weeks ago benzinga.com
Novavax Shorts on Edge as Russia Plague Fears Spread
Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $10 price target.
-
2 months ago benzinga.com
Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the…
-
2 months ago benzinga.com
Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray.…
-
2 months ago benzinga.com
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $12 to $10.
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
-
2 months ago benzinga.com
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
-
2 months ago benzinga.com
Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est
Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $720.000 million-$760.000 million to $645.000 million-$675.000 million vs $733.050 million estimate.
-
4 months ago benzinga.com
Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply
Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the…
-
4 months ago benzinga.com
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose
-
5 months ago benzinga.com
Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement
Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response…
-
5 months ago benzinga.com
U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide
https://www.cdc.gov/ebola/situation-summary/index.html
-
5 months ago benzinga.com
Emergent BioSolutions Announces Saudi Approval For ACAM2000, Its Smallpox and Mpox Vaccine
Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia)…
6 months ago benzinga.com
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
6 months ago benzinga.com
Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.
-
6 months ago benzinga.com
Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est
Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million to $720.000 million-$760.000 million vs $735.000 million estimate.
-
6 months ago benzinga.com
Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate
Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.25) by 184 percent. This is a 71.62 percent decrease over earnings of…
-
6 months ago benzinga.com
Emergent BioSolutions Receives Singapore's Health Sciences Authority Approval For Expanded Indication For ACAM2000
Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live)…
6 months ago benzinga.com
Earnings Scheduled For April 30, 2026
Earnings Scheduled For April 30, 2026
-
6 months ago benzinga.com
Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.Under the terms of the agreement, Emergent…
-
6 months ago benzinga.com
Emergent BioSolutions Signs ~$34.5M Agreement With Substipharm Biologics Over Drug Substance Production For Its Japanese Encephalitis Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its…
-
6 months ago benzinga.com
Emergent BioSolutions Collaborates With B.C. Provincial Health Services Authority To Provide Nasal Spray For Take-Home Naloxone Program
Emergent BioSolutions (NYSE:EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program…
-
7 months ago benzinga.com
Emergent BioSolutions Secures ~$54M Contract To Provide CNJ-016 Vaccinia Immune Globulin Intravenous To U. S. Department of Health And Human Services' Administration For Strategic Preparedness And Response For Smallpox Preparedness; Gets New $6.6M Incremental Orders With Undisclosed Global Federal Partner For ACAM2000
Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)]…
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $12
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $15 to $12.
8 months ago benzinga.com
Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED)
Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED)
8 months ago benzinga.com
Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results
U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares up 21% on Q4 earnings.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
8 months ago benzinga.com
Dow Dips Over 600 Points; US Producer Prices Increase In January
US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 months ago benzinga.com
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
8 months ago benzinga.com
Earnings Summary: Emergent BioSolutions Q4
Earnings Summary: Emergent BioSolutions Q4
-
8 months ago benzinga.com
Emergent BioSolutions Sees FY2026 Sales $720.000M-$760.000M vs $1.155B Est
Emergent BioSolutions (NYSE:EBS) sees FY2026 sales of $720.000 million-$760.000 million vs $1.155 billion analyst estimate.
-
8 months ago benzinga.com
Emergent BioSolutions Q4 Adj. EPS $(0.43) Misses $0.11 Estimate, Sales $148.700M Miss $217.500M Estimate
Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $0.11 by 490.91 percent. This is a 960 percent decrease over earnings of…
-
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
8 months ago benzinga.com
Emergent BioSolutions Wins FDA Approval For New Narcan Multipacks To Expand Overdose Access
Emergent BioSolutions Inc. (EBS) stock rose Friday as FDA approved new multipack configurations of over-the-counter NARCAN Nasal Spray.
-
8 months ago benzinga.com
Emergent BioSolutions Obtains FDA Approval For Its Supplemental New Drug Application For New Multipack Configurations Of OTC NARCAN Nasal Spray
Today, Emergent BioSolutions (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of…
9 months ago benzinga.com
Dirty Vaccines, Clean Cash: Emergent Ex-CEO Sued For Insider Trading
New York Attorney General sued the former CEO of Emergent BioSolutions, Robert G. Kramer, for insider trading.
-
9 months ago benzinga.com
Attorney General James Sues Former CEO Of Emergent BioSolutions For Insider Trading
https://ag.ny.gov/press-release/2026/attorney-general-james-sues-former-ceo-emergent-biosolutions-insider-trading
-
9 months ago benzinga.com
FDA Approves Emergent BioSolutions' sNDA For OTC NARCAN Nasal Spray To Be Packaged In New Carrying Case
Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN®…
-
9 months ago benzinga.com
Emergent BioSolutions Made Voluntary Prepayment Of $100M Under Its Outstanding Term Loan Facility In Late December 2025, Using Cash On Hand
"This significant milestone reflects strong progress in improving our overall financial/cash position, enhancing our financial flexibility and positioning Emergent for long-term stability and…
-
9 months ago benzinga.com
Emergent BioSolutions Bags Delivery Order Valued At Up To $21.5M From U.S. Department Of War To Supply BioThrax In 2026
Today Emergent BioSolutions (NYSE:EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026.…
-
10 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $15 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
1 year ago benzinga.com
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
1 year ago benzinga.com
Earnings Scheduled For October 29, 2025
Earnings Scheduled For October 29, 2025